Gentium S.p.A. announced today that it has been informed by the European Medicines Agency's Committee for Medicinal Products for Human Use that it has adopted a negative opinion, recommending the refusal of the marketing authorization for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing ... (more)
http://www.biospace.com/news_story.aspx?StoryID=291378&full=1
http://www.biospace.com/news_story.aspx?StoryID=291378&full=1
No comments:
Post a Comment